Mechanisms of Weight Loss With SGLT2 Inhibition

• Status: Completed
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese.

Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss.

The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: Janssen Scientific Affairs, LLC
• Treatments: Canagliflozin

Criteria

Inclusion Criteria:

1. Type 2 diabetes

2. BMI 25-45 kg/m2

3. Hemoglobin A1C > 6.5% but < 9%

4. Normal renal function (GFR > 60)

5. Age 18-75

Exclusion Criteria:

1. Type 1 diabetes

2. History of recurrent UTI or mycotic genital infections

3. Treatment with insulin or a GLP1 agent

4. Pregnant or breastfeeding